1. Critical research concepts in tuberculosis vaccine development
G. Delogu, R. Manganelli, M.J. Brennan 
Clinical Microbiology and Infection 
Volume 20, Pages (May 2014)
DOI: /
Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1.
Schematic showing a model of a typical anti-mycobacterial immune response based on T cells that may be induced by bacillus Calmette-Guérin and some of the vaccines currently under development. These vaccines elicit a T-cell immune response directed against Mycobacterium tuberculosis (Mtb) antigens and rapid mobilization of these T cells and recruitment of other leucocytes at the site of bacterial replication warrants a robust and more effective control of Mtb compared with non-immunized subjects. IFN-γ, interferon-γ; PMN, polymorphonuclear cells.
Clinical Microbiology and Infection  , 59-65DOI: ( / )
Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

3. FIG. 2.
Rationale for a vaccine strategy aimed at blocking transmission. (a) Vaccines may potentially prevent Mycobacterium tuberculosis (Mtb) transmission in two different ways. (I) By inducing an immune response that limits tissue damage and cavitation in lung tissues while not necessarily preventing infection or disease; (II) by inducing an immune response that prevents infection by enhancing antimicrobial responses occurring in the early steps of infection. (b) Development and evaluation of anti-infective vaccines require proper experimental models that mimic Mtb transmission. TB, tuberculosis.
Clinical Microbiology and Infection  , 59-65DOI: ( / )
Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions